Company Focus
Moderna
Latest Moderna News
Biotechnology
US clinical-stage biopharma Arbutus Biopharma saw its shares rise 4% to $4.70 in premarket activity today, as it announced initiation of patent infringement action. 16 July 2026
Related News
Insights
Company Spotlight
A Cambridge-based rare-disease biopharmaceutical company building a hematology franchise around its first-in-class pyruvate kinase activator mitapivat, now expanding into immune thrombocytopenia via a newly licensed SYK inhibitor.
Latest News & Features of interest to Moderna
Biotechnology
The European Commission has approved an expanded indication for Japan-based pharma company Kyowa Kirin’s Crysvita (burosumab), allowing the medicine to be used in infants from one month to under one year of age with X-linked hypophosphataemia (XLH). 21 July 2026
Biotechnology
Germany’s Allogenetics today announced the appointment of Dr Jeroen Rovers as chief medical officer (CMO). 21 July 2026
Pharmaceutical
French pharma Advicenne, which is developing treatments for people suffering from rare kidney diseases, announced that Sibnayal (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal renal tubular acidosis (dRTA). 21 July 2026
Biotechnology
US biotech Dyne Therapeutics has moved closer to a possible first approval after the US Food and Drug Administration accepted its biologics license application for zeleciment rostudirsen, or z-rostudirsen, in Duchenne muscular dystrophy. 20 July 2026
Biotechnology
US biotech Talawar Therapeutics today announced the appointment of Steve Migausky as chief legal and administrative officer. 20 July 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted Japanese pharma major Shionogi’s supplemental New Drug Application (sNDA) for Fetroja (cefiderocol) for the treatment of pediatric patients (at least 26 weeks of gestational age) with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain Gram-negative microorganisms. 20 July 2026
Pharmaceutical
US pharma major Bristol Myers Squibb is expanding its partnership with NVIDIA, with plans to deploy an NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems to support AI-led drug discovery and development. 20 July 2026
Pharmaceutical
The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate. 20 July 2026
Pharmaceutical
Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug Zegfrovy. Biogen released new Phase II data its Alzheimer’s candidate diranersen that raised questions. Celcuity won US Food and Drug Administration (FDA) for its investigational breast cancer drug Revtorpyk and Merck & Co announced FDA approval for its oral PCK9 cholesterol drug Lipfendra. Eli Lilly revealed plans to acquire mental health biotech AtaiBeckley for an upfront $2.8 billion. 19 July 2026
Pharmaceutical
The US Food and Drug Administration’s (FDA) approval of Utebzi (tebipenem pivoxil) gives physicians the first oral carbapenem option for adults with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. 17 July 2026
Latest In Brief for Moderna
Biotechnology
US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion. 20 June 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze